Our Pricing

Wegovy Cost With Private Prescription: UK Pharmacy Pricing Guide

Published on: June 03, 2026

Understanding wegovy cost private prescription uk options helps you make informed decisions about your weight management journey. At Cured Pharmacy, Wegovy (semaglutide) injections start from £79.00, with transparent upfront pricing and a free clinical consultation completed in under three minutes by our UK-registered prescribers.

What Determines Wegovy Cost With Private Prescription?

The cost of Wegovy through private prescription varies based on several clinical factors. Your prescribed dose strength—ranging from 0.25mg starter pens through to the 2.4mg maintenance dose—directly influences the monthly expenditure [1]. At Cured Pharmacy, we maintain competitive UK pricing starting from £79.00, with all costs displayed before you begin your consultation.

Unlike some providers who add hidden consultation fees or administrative charges, our pricing model includes your UK prescriber assessment at no additional cost. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives transparent pricing information before committing to treatment, reflecting our commitment to accessible weight management solutions.

The titration schedule also affects your overall investment. Wegovy follows a structured dose escalation protocol over 16-20 weeks, starting at lower doses to minimise gastrointestinal side effects before reaching the therapeutic 2.4mg weekly maintenance dose [1]. This clinically-validated approach means your initial months typically cost less than the maintenance phase.

How Wegovy Semaglutide Works for Weight Loss

Semaglutide, the active pharmaceutical ingredient in Wegovy, functions as a GLP-1 receptor agonist—mimicking a natural hormone that regulates appetite and food intake [2]. When administered as a once-weekly subcutaneous injection, it acts on areas of the brain responsible for appetite control, helping patients feel fuller sooner and reducing overall caloric consumption.

The STEP clinical trial programme demonstrated compelling efficacy data. In the pivotal STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks when combining Wegovy with lifestyle modifications, compared to 2.4% with placebo [2]. These results established semaglutide 2.4mg as one of the most effective pharmacological interventions for weight management licensed in the UK.

Clinical Eligibility Criteria

The MHRA has licensed Wegovy for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. During your free online consultation, our UK prescribers assess your medical history, current medications, and weight management goals to determine if Wegovy represents an appropriate treatment option for your individual circumstances.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss medications are now available through UK pharmacies, each with distinct mechanisms and clinical profiles. Semaglutide-based Wegovy targets the GLP-1 pathway exclusively, whilst newer dual-action treatments activate both GLP-1 and GIP receptors, potentially offering enhanced weight reduction in clinical trials [4].

Liraglutide represents an earlier-generation GLP-1 agonist requiring daily injections rather than Wegovy's convenient once-weekly administration. Whilst effective, the daily injection burden and shorter duration of action make weekly semaglutide a preferred option for many patients seeking sustainable treatment adherence.

Oral medications like orlistat work through an entirely different mechanism—blocking dietary fat absorption in the gastrointestinal tract. However, clinical trials show more modest weight reduction compared to GLP-1 receptor agonists, with average losses of 3-5% versus the 15% average seen with semaglutide in STEP trials [2][5].

Choosing Your Treatment Pathway

Your UK prescriber considers multiple factors when recommending a weight loss medication: your BMI and weight loss goals, medical history including cardiovascular risk factors, previous treatment responses, injection tolerance, and budget considerations. At Cured Pharmacy, we stock the full range of licensed weight management treatments, allowing your prescriber to select the most clinically appropriate option rather than limiting choices based on inventory constraints.

Wegovy Dosing Schedule and Treatment Duration

Wegovy follows a mandatory dose escalation protocol designed to optimise gastrointestinal tolerability. Treatment begins with 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose at week 17 [1]. This gradual titration significantly reduces the incidence of nausea and vomiting compared to starting at higher doses.

Clinical guidance suggests continuing Wegovy for at least 12 months to achieve optimal weight reduction, with many patients maintaining treatment long-term for weight maintenance [3]. In the STEP 4 trial, participants who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight, whilst those continuing treatment maintained their weight loss, highlighting the medication's role in long-term weight management rather than short-term intervention [6].

Our UK prescribers conduct regular clinical reviews—typically at 3, 6, and 12 months—to assess treatment response, monitor for adverse effects, and evaluate whether continuing Wegovy remains clinically appropriate. NICE guidance recommends discontinuing treatment if patients haven't achieved at least 5% weight loss after 12 weeks at the maintenance dose, ensuring resources focus on those deriving clinical benefit [3].

Common Side Effects and Management Strategies

Gastrointestinal side effects represent the most frequently reported adverse reactions with Wegovy. In clinical trials, nausea affected approximately 44% of participants, whilst vomiting, diarrhoea, and constipation occurred in 24%, 30%, and 24% respectively [2]. These effects typically emerge during dose escalation phases and diminish with continued treatment as physiological tolerance develops.

Practical management strategies significantly improve tolerability. Eating smaller, more frequent meals rather than large portions, avoiding high-fat foods that delay gastric emptying, staying well-hydrated, and timing injections consistently all help minimise gastrointestinal symptoms. If side effects prove problematic, your prescriber may slow the titration schedule, allowing additional time at each dose level before escalating.

Rare but serious adverse effects require immediate medical attention. These include signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, kidney impairment symptoms, or allergic reactions [1]. Our clinical team at Cured Pharmacy provides comprehensive patient information leaflets and remains available on (+44) 116 4646009 should you experience concerning symptoms during treatment.

Contraindications and Precautions

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1]. It's not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. Your UK prescriber reviews your complete medical history during consultation to identify any contraindications before prescribing.

Why Choose Cured Pharmacy for Your Wegovy Prescription

As a fully registered UK pharmacy (GPhC Registration Number 9012511), we dispense only genuine UK-licensed Wegovy sourced directly from authorised wholesalers. Every pen carries full product traceability and meets MHRA quality standards, giving you confidence in medication authenticity—a critical consideration when purchasing prescription medicines online.

Our clinical consultation process combines convenience with thorough medical assessment. The online questionnaire takes under three minutes to complete, yet captures all essential clinical information our UK prescribers need to make safe prescribing decisions. You'll receive a decision typically within hours, with discreet next-day delivery available across the UK once your prescription is approved.

We guarantee the lowest prices in the UK for Wegovy at £79.00, with transparent pricing displayed before you begin your consultation—no hidden fees, no surprise charges at checkout. Our commitment to accessible weight management extends beyond competitive pricing to include ongoing clinical support, with our pharmacy team available to answer questions throughout your treatment journey.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to lifestyle modifications.